# Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients

Study · id `cardio:ct-nct05735197` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05735197](<https://clinicaltrials.gov/study/NCT05735197>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05735197

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT05735197. Randomized; single masking; primary purpose prevention. Start 2022-09-01 (actual); primary completion 2023-08-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT05735197, source copy `cardio:ctgov-nct05735197-2024-11-08`, retrieved 2026-10-26)
- Started: 2022-09-01 (actual) (ClinicalTrials.gov record NCT05735197, source copy `cardio:ctgov-nct05735197-2024-11-08`, retrieved 2026-10-26)
- Primary completion: 2023-08-10 (actual) (ClinicalTrials.gov record NCT05735197, source copy `cardio:ctgov-nct05735197-2024-11-08`, retrieved 2026-10-26)
- Completion: 2023-11-01 (actual) (ClinicalTrials.gov record NCT05735197, source copy `cardio:ctgov-nct05735197-2024-11-08`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT05735197, source copy `cardio:ctgov-nct05735197-2024-11-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05735197-2024-11-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients
- Condition: Chronic Kidney Diseases
- Condition: Bone Diseases, Metabolic
- Intervention (Drug): Dapagliflozin 10mg Tab
- Intervention (Drug): Placebo
- Lead sponsor: Mansoura University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Mansoura University (`cardio:org-mansoura-university`)

## Provenance

Content hash: dd2ee625cce7580fe97eba092e5eee024d656b86e70127c475fa9588545f0877
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
